Becton, Dickinson and Company
Becton, Dickinson and Company
Your view on BDX
Overview
What the company does, where it operates, and who runs it.
About Becton, Dickinson and Company
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Thomas E. Polen Jr.
- Headquarters
- 1 Becton Drive, Franklin Lakes, NJ, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Thomas E. Polen Jr.
- Headquarters
- 1 Becton Drive, Franklin Lakes, NJ, US
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products.
The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Becton, Dickinson and Company from FRC's valuation model, read against the market price. BDX last traded at $216.47, 52.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Becton, Dickinson and Company. Starting points for Becton, Dickinson and Company: P/E 52.2, EPS $4.19, beta 0.28 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Becton, Dickinson and Company. Becton, Dickinson and Company paid $3.98 per share over the last year — a 1.8% yield at the current $216.47 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Becton, Dickinson and Company. Trailing twelve-month EPS for Becton, Dickinson and Company stands at $4.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$194.00
average of 10 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy7
- Hold5
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Sep 2027 | Next YearFY Sep 2028 |
|---|---|---|---|---|
| Avg. estimate | $2.35 | $3.02 | $13.25 | $14.23 |
| Low estimate | $2.28 | $2.98 | $13.12 | $13.85 |
| High estimate | $2.63 | $3.12 | $13.77 | $14.45 |
| No. of analysts | 8 | 8 | 8 | 8 |
| Year-ago EPS | $2.29 | $2.90 | $4.091 | — |
| Growth | +2.6% | +4.3% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Sep 2027 | Next YearFY Sep 2028 |
|---|---|---|---|---|
| Avg. estimate | $4.50B | $4.79B | $19.75B | $20.58B |
| Low estimate | $4.32B | $4.76B | $19.71B | $20.39B |
| High estimate | $5.19B | $4.82B | $19.83B | $21.14B |
| No. of analysts | 7 | 7 | 10 | 10 |
| Year-ago revenue | $5.25B | $4.71B | $19.46B | — |
| Growth | -14.4% | +1.6% | +1.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Becton, Dickinson and Company. Becton, Dickinson and Company has reported as a listed company since 1973. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABTAbbott LaboratoriesMedical - Devices$186.1B
- BAXBaxter International Inc.Medical - Instruments & Supplies$13.2B
- BLFSBioLife Solutions, Inc.Medical - Instruments & Supplies$1.9B
- EMBCEmbecta Corp.Medical - Instruments & Supplies$354M
- ICUIICU Medical, Inc.Medical - Instruments & Supplies$4.5B
- MDTMedtronic plcMedical - Devices$131.6B
- MMSIMerit Medical Systems, Inc.Medical - Instruments & Supplies$5.2B
- SOLVSolventum CorporationMedical - Instruments & Supplies$15.1B
More Medical - Instruments & Supplies companies
- STAASTAAR Surgical CompanyNASDAQ$1.3B
- STSSSharps Technology, Inc.NASDAQ$54M
- STVNStevanato Group S.p.A.NYSE$4.2B
- STXSStereotaxis, Inc.AMEX$80M
- SUVPFSartorius AGOTC$18.7B
- SVSOSheerVision, Inc.OTC$2,551
- TCGGYTecan Group AGOTC$2.3B
- TCHBFTecan Group AGOTC$2.2B
- TDVXFTobii Dynavox AB (publ)OTC$982M
- TFXTeleflex IncorporatedNYSE$6.2B
- TGLVYTop Glove Corporation Bhd.OTC$1.1B
- TRJ.AXTrajan Group Holdings LimitedASX
ETFs holding Becton, Dickinson and Company
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.08%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.07%
- VOVanguard Mid-Cap ETF$103.4B in assets0.52%
- IVViShares Core SP 500 ETF$852.9B in assets0.09%
- IHIiShares US Medical Devices ETF$4.0B in assets4.89%
- EQTYKovitz Core Equity ETF$1.4B in assets4.39%
- BASVBrown Advisory Sustainable Value ETF$434M in assets3.74%
- FPAGFPA Global Equity ETF$673M in assets3.57%
Largest holders first, then the funds most concentrated in BDX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Becton, Dickinson and Company, and how their positions are changing. At a $58.96B market value, institutional positions materially move Becton, Dickinson and Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Becton, Dickinson and Company executives and directors. Shares of Becton, Dickinson and Company have traded between $162.29 and $251.99 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Becton, Dickinson and Company. Becton, Dickinson and Company is a $58.96B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Becton, Dickinson and Company. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Becton, Dickinson and Company. Coverage tracks Becton, Dickinson and Company within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Becton, Dickinson and Company.